Volitionrx Limited · AMEX:VNRX

Volitionrx — Investor Presentation (November 2014)

17 slides from Volitionrx's investor presentation, November 2014

  1. Slide 1: VolitionRx: Revolutionizing Cancer Diagnosis

    VolitionRx Revolutionizing Cancer Diagnosis

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements Disclosure Statement The following discussion, in addition to the other information contained in this presentation, should be considered carefully in evaluating our prospects. This presentation (including without limitation the following factors that may affect operating

  3. Slide 3: About VolitionRx

    3 About VolitionRx About VolitionRx WHO WE ARE  US OTC-quoted company (VNRX)  Lab and head office in Namur, Belgium, Europe WHAT WE DO  Diagnostics company developing blood tests for cancers, beginning with colorectal cancer (CRC) HOW WE DO IT  4,800-individual clinical trial in Denmark (analysi

  4. Slide 4: Seasoned Leadership Team

    4 Seasoned Leadership Team Seasoned Leadership Team MANAGEMENT President & CEO, Cameron Reynolds MBA  20+ years entrepreneurial executive expertise; strong experience in management, structuring and strategic planning of start-up companies  Previous appointments with Integrated Coffee Technologies;

  5. Slide 5: Seasoned Leadership Team

    5 Seasoned Leadership Team Seasoned Leadership Team SCIENTIFIC EXECUTIVES CSO, Belgian Volition, Jake Micallef PhD MBA  20+ years in R&D and management of early stage biotech companies  Previous appointment with World Health Organization, developed diagnostic products in reproductive health and ca

  6. Slide 6: Company Highlights

    6 Company Highlights Company Highlights LANDSCAPE  Blood-based tests are the future of cancer diagnostics – higher compliance rates than current tests (colonoscopy and fecal tests)  Initial CRC target market: 150m in Europe1 / 87m in USA2 in recommended screening cohort (aged ~50-753)  Colorectal

  7. Slide 7: Significant Need for Better CRC Diagnostics

    7 Significant Need for Better CRC Diagnostics Significant Need for Better CRC Diagnostics Current CRC diagnostics:  Colonoscopy – accurate but invasive and expensive; low compliance  FIT/FOBT fecal-based tests – unpleasant; don’t pick up precancerous polyps; compliance problems Blood optimal for e

  8. Slide 8: The Market for Colorectal Cancer Tests

    8 The Market for Colorectal Cancer Tests The Market for Colorectal Cancer Tests THE EUROPEAN MARKET FOR CRC 432,000 New CRC cases in Europe p/a1  The European Union (EU) recommends FOBT (fecal) screening for colorectal cancer in all men and women aged $1.6bn 50 to 744  There are approximately 150m

  9. Slide 9: Nucleosomics – Overview

    9 Nucleosomics® – Overview Nucleosomics® – Overview  The DNA in every cell is wound around DNA Strand protein complexes in a “beads on a string” structure  Each individual “bead” is called a Nucleosomes nucleosome  When a cell dies, the body breaks the Nucleosomes Entering DNA string up into indi

  10. Slide 10: Nucleosomics – Technical Overview

    10 Nucleosomics® – Technical Overview Nucleosomics® – Technical Overview  Nucleosome "beads" consist of DNA wrapped around a core of histone proteins  Each core consists of four pairs of variants of H2A, H2B, H3 and H4 histones  Histones and the DNA are subject to a variety of post translational

  11. Slide 11: NuQ Test – Blood-based CRC Diagnostic

    11 NuQ® Test – Blood-based CRC Diagnostic NuQ® Test – Blood-based CRC Diagnostic LEVERAGES PROPRIETARY NUCLEOSOMICS® TECHNOLOGY  NuQ® tests identify and measure circulating nucleosome structures for the presence of epigenetic cancer signals within blood  In several trials, have been shown to:  Di

  12. Slide 12: Clinical Milestones

    12 Clinical Milestones 2014-Future (Colorectal Cancer) Clinical Milestones Q1-Q2 2014 Q3-Q4 2014 Q1-Q2 2015 Q3-Q4 2015 2016 on… Denmark: Release of Release of full Retrospective preliminary data data from first CRC Clinical set from first 4,800-subject Trial 4,800-subject Danish CRC Danish CRC trial

  13. Slide 13: Multiple Clinical Trials

    13 Multiple Clinical Trials Multiple Clinical Trials Hvidovre Hospital University of Copenhagen, Denmark (Professor Hans Jorgen Nielsen):  4,800-subject Danish CRC trial: Retrospective study analyzing samples collected in 2010-2012 of approx. 4,800 patients with CRC, polyps or adenomas, benign bowe

  14. Slide 14: New Positive Data

    14 Key Validation from ~1,000-Subject Sample New Positive Data SIGNIFICANT ACCURACY DEMONSTRATED  4,800-subject Danish CRC Study Design  Samples of patients with CRC, polyps or adenomas, benign bowel diseases and other malignancies, all of whom have undergone a colonoscopy  Symptomatic subjects (

  15. Slide 15: Additional Results to Date

    15 Strong Results to Date Additional Results to Date  Presented at the International Society of Oncology and Biomarkers Congress, March 2014  Findings in both prostate (PRC) and colorectal (CRC) cancers released  Colorectal cancer  86% detection at 86% specificity  50% detection of precancerous

  16. Slide 16: Finance at a Glance

    16 Finance at a Glance Finance  Listed on the OTC Markets in the U.S. under symbol VNRX  Total shares issued & outstanding (as of 30 Sept 2014): 14,308,960  Fully Diluted: 19,368,184  Market cap (as of 4 Nov 2014): $49m  More than 35% held by insiders  Investment since Dec 2010:  US~$13m  No

  17. Slide 17: Contact

    17 VolitionRX OTCBB: VNRX Contact Web: volitionrx.com CEO: Cameron Reynolds c.reynolds@volitionrx.com CSO: Jake Micallef j.micallef@volitionrx.com Director of Investor Relations: Scott Powell s.powell@volitionrx.com Communications Manager: Charlotte Reynolds charlotte.reynolds @volitionrx.com The Ru

VolitionRx — Investor Presentation (November 2014) on 6ix